AbbVie in Anti-Inflammatory Drug Pact
AbbVie has formed a collaboration with Zebra Biologics, an emerging preclinical-stage biotechnology company headquartered in Concord, Massachusetts, to discover agonist antibody therapeutics for inflammatory diseases.
Under the agreement, Zebra will lead the discovery of candidate agonist antibodies for designated targets and will collaborate with AbbVie in preclinical validation of select clinical candidates. Upon advancement of clinical candidates, AbbVie would be responsible for clinical development, manufacturing, regulatory approval, and worldwide commercialization. Financial terms were not disclosed.
Zebra will use its patented function-based antibody-screening platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie. Zebra and AbbVie will collaborate on the identification and preclinical evaluation of emerging candidates. The targets were not disclosed.